ArticleJTO clinical and research reports2024

Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study.

Jonathan W Riess et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.